What NuChem Sciences does

NuChem Sciences is a Canada-based contract research organization (CRO) headquartered in Montréal with additional operations in Lévis, Quebec, that provides integrated small-molecule and emerging-modality drug discovery services to pharmaceutical and biotechnology sponsors. Its core offering is a fully integrated drug discovery platform that progresses programs from target identification through pre-clinical candidate nomination, delivered via co-located expert teams and organized into seven scientific modules: Computer Aided Drug Design (CADD), Protein & Structure, Bioscience, Chemistry, Drug Metabolism & Pharmacokinetics (DMPK), in vivo Pharmacology, and Form & Formulation. Service breadth spans medicinal and process chemistry, structural biology (X-ray crystallography, cryo-EM, NMR), assay development, high-throughput screening, ADME/PK, and disease-specific in vivo models across oncology, neuroscience, inflammation/immunology, and metabolic disease. The company also maintains capability across multiple modalities — small molecules, peptides, targeted protein degradation, antibody-drug conjugates, and biologics — and on specialized target classes such as ion channels, GPCRs, and transporters.

The underlying technology stack combines wet-lab scientific infrastructure with a computational layer anchored on the SygDesign informatics platform, machine-learning-driven ADMET prediction, PK/PD modeling and simulation, and an embedded partnership with Iktos for the Makya generative AI engine used in de novo compound design. NuChem is privately held and, following its 2023 integration with Sygnature Discovery (alongside Peak Proteins and SB Drug Discovery), now operates as part of a unified CRO group of 700+ scientists spanning Europe and North America, with reported headcount in the 1,001-5,000 range for the combined entity. NuChem's commercial model is service-based: it sells FTE-driven drug discovery programs and modular scientific work packages to biopharma sponsors; no public pricing or sponsor logos are disclosed. The firm has funded inorganic expansion through a C$37.6 million raise in 2021 (led by Fonds de solidarité FTQ, with BDC and Investissement Québec) and executed acquisitions of OmegaChem (2021) and IniXium (2022) prior to its consolidation into the Sygnature Discovery brand.

Name

NuChem Sciences

Legal name

NuChem Sciences Inc.

Website

https://nuchemsciences.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

NuChem Sciences is a Montréal- and Lévis-based contract research organization providing integrated drug discovery services — from target identification to pre-clinical candidates — across medicinal chemistry, DMPK, structural biology, and in vivo pharmacology, to pharmaceutical and biotechnology sponsors, now operating as part of the unified Sygnature Discovery group.

Ownership category

akta.pro rank

Product category

Contract Drug Discovery Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Drug discovery services
• Medicinal chemistry
• Contract research organization
• Preclinical development
• Computer aided drug design

Headquarters

HQ city

Quebec

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

NuChem Sciences provides integrated drug discovery services as a contract research organization (CRO), running client-sponsored programs from target identification through to pre-clinical development. The offering is delivered through co-located teams combining medicinal chemistry, biology, DMPK, in vivo pharmacology, and formulation, with computer-aided drug design, AI/ML, and the SygDesign informatics platform supporting the workflow. Clients include pharmaceutical and biotechnology companies that outsource chemistry-led discovery work on a project basis.

Product overview

NuChem Sciences operates as an integrated drug discovery contract research organization (CRO) offering a unified platform combining scientific services across the full drug discovery pipeline. The core offering is Integrated Drug Discovery, supported by specialized modules including Computer Aided Drug Design (CADD), Protein & Structure, Bioscience, Chemistry, DMPK, in vivo Pharmacology, and Form & Formulation. These modules work together as connected services, with AI and automation powering cross-disciplinary workflows. Additional offerings include modality-specific services (Small Molecules, Peptides, Targeted Protein Degradation, ADCs, Biologics), target class expertise (Ion Channels, GPCRs, Transporters), and therapeutic area focus (Oncology, Neuroscience, Inflammation & Immunology, Metabolic Diseases). Note: Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated Drug Discovery Fully integrated drug discovery programs delivering compounds from target identification to pre-clinical development through co-located expert teams powered by AI and automation. Offered to pharmaceutical and biotechnology sponsors that outsource end-to-end discovery work.
• Computer Aided Drug Design (CADD) AI-powered modelling combining structure- and ligand-based design, predictive modelling, virtual screening, ADMET prediction, and informatics to reduce risk and timelines across drug discovery stages. Served to discovery teams needing computational chemistry support.
• Protein & Structure High-quality protein expression, purification, and characterization services combined with X-ray crystallography, cryo-EM, and NMR structural biology capabilities. Served to discovery programs needing structural insights and protein reagents.
• Bioscience Assay development, cell line generation, high-throughput screening, electrophysiology, and biophysical assays for target validation through candidate nomination. Served to discovery teams requiring biological screening and assay support.
• Chemistry Medicinal chemistry, synthetic chemistry, process chemistry, and high-throughput chemistry services scaling from milligram to kilogram quantities. Served to discovery and development programs needing compound design, synthesis, and scale-up.
• Drug Metabolism and Pharmacokinetics (DMPK) Integrated ADME screening, bioanalysis, pharmacokinetics, biotransformation, and PK/PD modelling to guide candidate selection and dose optimization. Served to discovery programs evaluating compound exposure, metabolism, and safety.
• in vivo Pharmacology Disease-specific in vivo models including CNS/pain, metabolic, inflammation/immunology, and oncology, combined with pharmacokinetics and exploratory toxicology. Served to discovery programs needing efficacy and PK/PD readouts in animal models.
• Form & Formulation Early clinical formulation, solid form analysis, salt/co-crystal screening, polymorph screening, and pre-clinical formulation development services. Served to discovery and development programs preparing compounds for pre-clinical and early clinical studies.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Partnerships

One partnership is on record.

• OmegaChemmajorOthers · 18 August 2021NuChem Sciences announced a C$37.6 million fundraising in August 2021 specifically to acquire OmegaChem. The funding was aimed at facilitating the acquisition process and strategic expansion of NuChem's operations.

Scale indicators1 record

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Pharmaron: China-rooted, globally integrated CRO/CDMO with strong medicinal chemistry, DMPK, biology, and in vivo pharmacology offerings. Directly comparable service portfolio to NuChem/Sygnature with growing UK/US presence to access Western biotech customers.
• Eurofins Discovery: Division of Eurofins Scientific offering drug discovery services including medicinal chemistry, ADME, and pharmacology. Comparable in service mix but operates as part of a much larger life-sciences testing conglomerate with broad capabilities beyond discovery.
• Charles River Laboratories: One of the largest pre-clinical CROs globally with extensive discovery, safety assessment, and manufacturing services. Overlaps with NuChem in medicinal chemistry, DMPK, and in vivo pharmacology, but operates at much greater scale with a US-centric footprint.
• WuXi AppTec: China-headquartered CRO offering end-to-end discovery, pre-clinical, and clinical services including medicinal chemistry and DMPK. Competes directly with NuChem on chemistry services, with significant cost-arbitrage advantages though geopolitical risks increasingly affect US/EU client preferences.
• Evotec SE: Global integrated drug discovery CRO offering target ID through pre-clinical services across multiple modalities and therapeutic areas. Directly comparable in scope and integrated-service model, but at significantly larger scale with broader geographic reach.

Emerging players

• Reaction Biology: Pre-clinical CRO specializing in biochemical and cell-based assays, biophysics, and medicinal chemistry support. Overlaps with NuChem's bioscience and chemistry modules but with a narrower therapeutic-area focus and smaller scale.

Direct peers

• Domainex: UK-based integrated drug discovery CRO offering medicinal chemistry, DMPK, structural biology, and bioscience services. Closely comparable in size, scope, and integrated-service delivery model, and now part of the same Sygnature Discovery group post-merger.
• ChemPartner: China and US-based integrated chemistry and biology CRO with strong medicinal chemistry, DMPK, and in vivo services. Comparable service scope and biotech client base to NuChem, competing primarily on cost and scale rather than modality breadth.
• BioDuro: Integrated drug discovery and pre-clinical CRO offering medicinal chemistry, DMPK, biology, and pharmacology services. Comparable in service portfolio and target customer segment (mid-cap pharma and biotech), with significant operations in China and the US.
• Sygnature Discovery: Parent organization into which NuChem was fully integrated in 2023. Operates the same integrated drug discovery model (medicinal chemistry, DMPK, bioscience, in vivo pharmacology) from the UK, making it the most direct functional peer — though now part of the same corporate entity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCWUzxh2tPSL0Oer35E8tWow
• LinkedInlinkedin.com/company/nuchem-sciences
• Xx.com/NuchemSciences
• Facebookfacebook.com/nuchemsciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NuChem Sciences